Written Question · S2W-18941 · Session 2
What quantities of avian influenza vaccine will be held centrally in Scotland and what quantities will be dispersed around the country.
The question
To ask the Scottish Executive what quantities of avian influenza vaccine will be held centrally in Scotland and what quantities will be dispersed around the country.
The answer
Although the avian influenza virus poses a risk to birds its risk to humans is extremely limited. This is because it is very difficult to catch from birds and even more difficult to pass from human to human. The major concern is the possibility that the virus could mutate into a form that can transmit easily between humans, and thus give rise to another influenza global epidemic (a pandemic) in humans.
A vaccine made from the H5N1 strain currently circulating in south east Asia may offer some protection should a pandemic strain emerge from this particular virus in the near future. While the degree of protection offered by such a vaccine could not be known prior to a pandemic, as a precautionary measure, the Scottish Executive is purchasing a small quantity of a vaccine against the current H5N1 strain. 270,000 doses for priority groups such as NHS workers have so far been ordered. The UK Pandemic Influenza Contingency Plan sets out issues around the production of specific vaccine for the virus causing pandemic flu.
Arrangements for stockpiling of the limited quantity of H5N1 that has been ordered are still under discussion. However, when available, the vaccine will be held in Scotland in appropriate vaccine holding premises. The H5N1 vaccine will require refrigeration.
The shelf-life of the H5N1 vaccine will be based on the results of stability testing and agreed with the licensing authority at the time of licensing.
A vaccine made from the H5N1 strain currently circulating in south east Asia may offer some protection should a pandemic strain emerge from this particular virus in the near future. While the degree of protection offered by such a vaccine could not be known prior to a pandemic, as a precautionary measure, the Scottish Executive is purchasing a small quantity of a vaccine against the current H5N1 strain. 270,000 doses for priority groups such as NHS workers have so far been ordered. The UK Pandemic Influenza Contingency Plan sets out issues around the production of specific vaccine for the virus causing pandemic flu.
Arrangements for stockpiling of the limited quantity of H5N1 that has been ordered are still under discussion. However, when available, the vaccine will be held in Scotland in appropriate vaccine holding premises. The H5N1 vaccine will require refrigeration.
The shelf-life of the H5N1 vaccine will be based on the results of stability testing and agreed with the licensing authority at the time of licensing.
In the Official Report
No contribution in the Official Report cites S2W-18941 by reference.